Aminoacyl-transfer RNA (tRNA) synthetases (ARSs) are crucial for protein translation. The number of identified patients with mitochondrial (mt)ARS-deficiencies is rapidly increasing, but treatment is limited to supportive care. Recently, cognate amino acid supplementation has been explored. Early diagnosis and insights into the natural history are necessary to evaluate potential treatment effects.